晚期非小细胞肺癌一线治疗新药阿法替尼  

New First-line Treatment Drug for Advanced Non-small Cell Lung Cancer-Afatinib

作　　者：安富荣[1] 王淑萍[1] 归小龙[1] 

机构地区：[1]上海交通大学医学院附属仁济医院药剂科,上海200001

出　　处：《中国药师》2015年第1期136-138,共3页China Pharmacist

摘　　要：阿法替尼是一种口服给药的酪氨酸激酶Erb B家族不可逆抑制药。两项随机、开放标签、多中心Ⅲ期临床试验结果表明,与培美曲塞+顺铂(LUX-Lung 3)或吉西他滨+顺铂(LUX-Lung 6)化疗相比,阿法替尼可显著延长EGFR突变的晚期非小细胞肺癌患者的无进展生存期,患者报告的咳嗽和呼吸困难症状以及健康相关生活质量也优于化疗组。阿法替尼于2013年7月获得美国FDA批准上市,一线治疗伴EGFR外显子19缺失或外显子21替代突变的晚期非小细胞肺癌。本文对阿法替尼的作用机制、药动学特性、临床研究进展以及安全性等作一综述。Afatinib is an irreversible inhibitor for the ErbB family of tyrosine kinases with oral administration. In two randomized, open-label and multinational phase III trials, the progression-free survival was significantly prolonged by afatinib compared with peme-trexed plus cisplatin （LUX-Lung 3） or gemcitabine plus cisplatin （LUX-Lung 6） in the treatment-naive patients with advanced non-small cell lung cancer （ NSCLC） with activating EGFR mutations. The patient-reported symptoms such as cough and dyspnoea, and certain health-related quality of life after the treatment by afatinib were also better than those treated by control dugs. Afatinib was ap-proved by FDA in July 2013 as the first-line treatment drug for the patients with metastatic NSCLC with EGFR exon 19 deletions or exon 21 （L858R） mutations. The action mechanisms, pharmacokinetics, clinical trials and adverse events were reviewed in this paper.

关 键 词：阿法替尼 表皮生长因子受体 晚期非小细胞肺癌 临床研究 

分 类 号：R743.2[医药卫生—神经病学与精神病学]